![Alan D. Watson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Alan D. Watson
Corporate Officer/Principal chez
Targeted Diagnostics & Therapeutics, Inc.
Profil
Dr. Alan D.
Watson is a Director at IMCOR Pharmaceutical Co., Vice President-Business Development at SmartCells, Inc., and Entrepreneur-in-Residence at Oxford Bioscience Partners.
He is on the Board of Directors at IMCOR Pharmaceutical Co. and Targeted Diagnostics & Therapeutics, Inc.
Dr. Watson was previously employed as Senior Vice President-Corporate Development by Cubist Pharmaceuticals, Inc.
He received his undergraduate degree from The University of New South Wales, an MBA from Northeastern University, and a doctorate degree from Australian National University.
Postes actifs de Alan D. Watson
| Sociétés | Poste | Début |
|---|---|---|
Targeted Diagnostics & Therapeutics, Inc.
 Targeted Diagnostics & Therapeutics, Inc. Medical SpecialtiesHealth Technology Develops molecular diagnostics and therapeutics | Corporate Officer/Principal | - |
Anciens postes connus de Alan D. Watson
| Sociétés | Poste | Fin |
|---|---|---|
Oxford Bioscience Partners
 Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Corporate Officer/Principal | - |
| CUBIST PHARMACEUTICALS INC | Corporate Officer/Principal | - |
SmartCells, Inc.
 SmartCells, Inc. Medical SpecialtiesHealth Technology Develops breakthrough treatment for diabetes called SmartInsulin | Corporate Officer/Principal | - |
IMCOR Pharmaceutical Co.
 IMCOR Pharmaceutical Co. Medical SpecialtiesHealth Technology Develops medical imaging pharmaceutical products | Directeur/Membre du Conseil | - |
Formation de Alan D. Watson
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
3
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Engages in research, development and commercialization of pharmaceutical products | Health Technology |
Oxford Bioscience Partners
Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Finance |
IMCOR Pharmaceutical Co.
IMCOR Pharmaceutical Co. Medical SpecialtiesHealth Technology Develops medical imaging pharmaceutical products | Health Technology |
Targeted Diagnostics & Therapeutics, Inc.
Targeted Diagnostics & Therapeutics, Inc. Medical SpecialtiesHealth Technology Develops molecular diagnostics and therapeutics | Health Technology |
SmartCells, Inc.
SmartCells, Inc. Medical SpecialtiesHealth Technology Develops breakthrough treatment for diabetes called SmartInsulin | Health Technology |
Australian National University
 Australian National University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Northeastern University
 Northeastern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of New South Wales
 The University of New South Wales Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
